The erects of oral contraceptives have been studied in the beagle bitch for periods up to 7 yr. High doses of these potent estrogen: progestogen (EP) combinations have been shown to promote tumors in the mammary glands, smooth muscle of the tubular genitalia, and occasionally in the transitional epithelium of the necWtrigone area of the urinary bladder. The contraceptive formulations used in humans are balanced with an E P ratio of about 1:5 to 1:80 to produce a desired decidual response in the uterus. The corresponding ratio for producing the decidual reaction in the dog is 1:1,000 to 1:3,000 with the result that the dog is grossly overdosed with estrogens when given the human formulation at the usual multiples of up to 25 times the human dose. Smooth muscle tumors of the tubular reproductive tract are common sequelae to estrogen overstimulation in the dog and are known to occur in other species, including the human. The dog also has major differences in hormonal control and sensitivity when compared to humans. Progestogens stimulate synthesis and release ofgrowth hormone (GH) in dogs which in turn is the major stimulant (with progestogens) of mammary growth and tumors. Evidence is accumulating which indicates that most if not all progestogens can produce mammary tumors in the dog ifgiven by the correct route and at high enough dosage. In contrast, G H in humans is not increased nor does it have any significant mammotrophic role. Mammary tumors in . dogs related to oral contraceptives are now widely considered to be irrelevant as a model or predictor for human tumors. Transitional cell tumors in the urinary bladder seem to be a species specific phenomenon seen on occasion in the dog, but not in the rat, monkey, or human. The usual location in the necWtrigone area may be related to the embryologic origin of this portion of the bladder, which derives from tissues more closely related to the genital organs than does the rest of the bladder.
INTRODUCTION ... The laboratory beagle dog has been a commonly' used species in the safety evaluations of new drug candidates, where studies of up to 1 yr in length are required. In the development of oral contraceptives, 2-yr studies are also done (2) . As a result of 1 of these 2-yr studies, the dog became a pivotal species with a unique place in the history of oral contraceptive drug development: it was the development of mammary nodules in this species from the progestogen MK-665 that precipitated the requirement (in 1967) for long-term 7-and 10-yr studies in dogs and monkeys, respectively (2) . Additionally, the mammary nodule problem in dogs is also largely responsible for the present dominance of the US oral contraceptive market by progestins derived from the 19-nortestosterone series of compounds rather than those of the 17-hydroxyprogesterone series (1 , 3, 19) .
Over 20 yr have passed since the long-term studies were first mandated by the Food and Drug Administration (FDA) and most of these studies have been completed. It is appropriate at this time to review, in general terms, what these studies have demonstrated and to determine if the findings were appropriate for extrapolation to humans. As with most animal models, the dog has advantages and disadvantages in regard to oral contraceptive safety predictions. Some findings predict a human risk, some do not, and some are irrelevant because of species differences.
This review will consider tumors primarily, since that was the focus of the studies, but will also touch 389 JOHNSON .
TOXICOLOGIC PATHOLOGY 
Mestranol (MEE) Ethinyl estradiol (EE) 1. MEE is converted largely to EE by mammalian liver 2. EE is by far the more active drug 3. EE is 1.5 to 2 times as potent as MEE on a weight basis 4. EE has largely replaced MEE in the oral contraceptive formulations
briefly on non-tumor findings of interest. The' findings in the dog are better understood if the reader is aware of some properties of the drugs and certain unique endocrine features of the canine, which are given below.
BACKGROUND INFORMATION Drug Classes
Estrogens. The oral contraceptives are of 2 types: estrogen combined with progestin (EP) or progestin only. The estrogenic component in the US market consists almost exclusively of either mestranol (MEE) or ethinyl estradiol (EE) (Table I) . Early contraceptives mostly contained MEE, but it was found that MEE was not a particularly active molecule. The mammalian liver extensively converts MEE to EE (3) which is the most active form. EE has largely replaced MEE in the later formulations of the oral contraceptives. On a weight basis, EE is estimated to be 1.5 to 2 times more active than MEE (8).
Progestiits. The progestin portion ofthe oral contraceptives is much more varied than the estrogen, with at least a dozen different versions on the market (Table 11) . For the purposes of considering the dog studies, it is convenient to divide them into 2 groups of compounds, the 19-nortestosterone group, and the, 17-hydroxyprogesterone group. Each progestin has its own distinct profile of activity relative to the natural progesterone. This profile includes the relative progestin potency, dny glucocorticoid effect, i the presence of inherent estrogenic or anti-estrogenic activity, possible androgenic (testosterone) activity and any antiandrogenic activity (4). Androgenic activity, for example, could induce unwanted hirsutism (body and facial hair growth) in humans. As another example, the 19-nortestosterone progestins tend to have pronounced estrogenic activity in mice 
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and rats (1, 4) and to some extent in dogs (27) but not in the human. A single progestin does not have equal effects in each species. It has been found that progestins having strong progestational activity in the human (the 19-nortestosterones) are usually weakly progestational in the dog, and conversely strong progestins in the dog (the 17-hydroxyprogesterones) tend to be more weakly active in humans (1, 4, 11). This species difference has been of great importance in the canine studies since (as will be noted later) the development of mammary nodules and tumors is directly.related to progestin activity.
Unique Endocrine Features of the Dug
The dog has several differences from the human in the endocrine control and/or endocrine sensitivities of organs which are relevant to oral contraceptive use (Table 111) .
Estrogeii Toxicity. Estrogens are generally considered to be very non-toxic substances in acute doses but it is not widely known, at least outside of veterinary circles, that the canine is the only common animal that can be killed by an overdose of estrogens (19, 20, 31, 33) . This sensitivity (shared perhaps by the ferret) (31) is due to bone marrow suppression and resulting aplastic anemic which can be fatal. Other species (including man) do not share this sensitivity but do show a slight decrease in red blood cell parameters. The exact mechanism is not completely understood but it appears that estrogens block the utilization of erythropoietin by pluripotential stem cells in the marrow (33). It is recommended that dogs not receive the estrogen diethylstilbestrol (DES) in amounts over 1 mg per pound or 20 mg total (31) . The activity of estradiol is reported to be at least 10 times that of DES (31) .
Uterine Eiidoi net rial Sensitivity to Progestim.
The dog uterine endometrial tissue, once it is primed by estrogen, is very sensitive to the stimulatory effect of progestins (1 5). Under the prolonged influence of progestins, the uterus undergoes an endometrial hyperplasia which often becomes cystic in nature (28) . The uterine glandular secretions tend to accumulate which provide a felicitous growth medium for bac-terial invaders. Since progestins also inhibit the leukocytic response in the endometrium (21), any infection can easily give rise to generalized endometritis and pyometra. Pyometra in the dog is often a life-threatening condition requiring prompt medical attention, usually requiring surgical removal of the affected uterus.
Maminary Stiititilation by Progestins. Stimulation of the mature mammary gland is not accomplished by the same mechanism in all mammalian species. Progestins are an integral part ofthis process but they must be facilitated by other hormones. In the murine species (e.g., rat and mouse), estrogen and prolactin are the additional factors needed (1) while in the monkey and human, estrogen plus a placental factor and perhaps a novel pituitary hormone are apparently required (1,13). The dog differs from these species in that growth hormone (GH) is the definitive additional promoter needed to stimulate mammary tissue (1 , 1 1). Growth hormone has no major mammary stimulatory role in the other species studied (13) . Excessive amounts of GH in the dog result in increased numbers of palpable mammary nodules, some of which are neoplastic. It is of prime interest to note that progestins stimulate the dog pituitary to release GH in direct relationship to the potency or dose of the progestin used (1). Thus, in the dog, progestins alone can stimulate mammary tissue by also stimulating the production of the needed co-factor, GH.
Estrogen : Progestin Ratio. The estrogen : progestin (E:P) ratio of a combination oral contraceptive must be within a certain range in order to achieve the desired contraceptive effects plus maintenance of a physiologic homeostasis. As a measure of a desirable effect, the decidual response of the uterus has been used as a bench mark for comparison. This response involves the enlaigement of uterine strom-, a1 cells in a manner preparatory to support a preg-' nancy and requires a proper balance between estrogens and progestins. In the human such a response occurs when the E P ratio ranges from approximately 1:5 to 1:80, depending on the particular progestin compounds used, and it is similar for monkeys (1). The dog and rat have entirely different requirements. The dog optimum E:P ratio is approximately 1:1,000 to 1:3,000 while the rat is around 1: 10,000-26,000 (1 , 13, 35) . Administration of human formulations to the dog, therefore, results in a gross overdose of the estrogenic component and the creation of a non-physiologic hormonal milieu.
St tidy Design
The long-term studies in dogs (and monkeys for that matter) were promulgated primarily to address the mammary nodule problem mentioned earlier.
For dogs, a 7-yr period was designated because it represented at least half of the life-span of this species (2) which correlated with the supposition that women taking oral contraceptives could do so for up to half of their likely life-span. It was also felt that any spontaneous mammary tumors would likely appear by this time. A secondary objective was to observe for evidence of any clotting or other coagulation disorders from long-term dosing (23, 34) . Most studies used between 15 and 20 dogs per dose group.
The multiples of drug to use in the dog studies were controversial. The primary concern was that the administration of high doses of estrogens for such a prolonged period might result in bone marrow depression and anemia. A secondary concern was that the high doses of progestins, with the expected effect of producing cystic endometrial hyperplasia, would trigger so many cases of pyometra (as discussed earlier under endometrial sensitivity) that the mortality rate would be unacceptable-The resulting agreement between the FDA and the industry set the upper multiple at 25 times the human dose (2, 20). Even under those circumstances there were several studies in which all dogs were hysterectomized prior to the study initiation, or within 1 to 4 yr of the study start as cystic hyperplasia and pyometras developed in numbers deemed unacceptable (9, 12, 14, 34) . It is ironical that there are drugs currently marketed in some countries which received regulatory approvals without information on a key target organ in this species, while other drug studies in which the uterus was preserved triggered questions by regulatory agencies concerning smooth muscle tumors seen in the uterus.
RESULTS AND DISCUSSION
The results of the various 7-yr dog studies have some variability depending on the specific compounds administered. The generally applicable findings are presented below. For convenience, they are divided into clinical, clinical pathologic, and pathologic findings with discussion as appropriate.
Clinical Findirigs (Table I v)
Other than the expected pyometra cases encountered in a dose-related manner, the main clinical findings involved a redistribution of body fat with areas of symmetrical loss of body hair and a potbellied "Cushingoid" appearance (1 7). Mammary hyperplasia and nodules were generally encountered earlier and more frequently in treated animals in a dose-related pattern (1 1, 12). In some cases, dogs developed a thickening of skin and bones known as acromegaly (1 1, 20) . These effects are further discussed below. (Table v) The clinical pathologic findings Of interest sometimes took years to express themselves and could be quite variable both within groups and within individual dogs. Overall, there was a dose-related increase in liver enzymes (ALT/SGPT); increased glucose level, decreased red blood cell indices such as hematocrit and hemoglobin, and increased prothrombin time (PT), often with increased platelet numbers (18, 34). In many cases, these parameters were still within acceptable normal limits.
The increase in liver enzymes is not completely understood but may be related to the increased bur: den on the liver for the metabolism and excretion of the drugs. The increased PT time may also be reflective of the role of the liver in supplying the appropriate clotting factors while under stress. The reduced red blood cell indices are related to the known depressive effects of estrogen on the bone marrow. The occasional increased glucose levels reflect a decreased glucose tolerance. Growth hormone is known to decrease glucose uptake in muscle and to mobilize fatty acids from adipose tissue (16) . There is a resulting hyperglycemia, and this may be an explanation for the glucose increase in the dog. However, there is some indication that progestins can .have an anti-insulin effect by decreasing the number of insulin receptors (7) . Some humans do have reported increases in ,blood glucose but it is apparently unrelated to GH, which in man is relatively unaffected by oral contraceptives. A pathologic effect is described under the pancreas islets which may be related. (Table VI) Liver. The liver sometimes contains areas of focal nodular hyperplasia in a dose related manner (17, 18) . These nodules are clearly non-tumorous and can be found spontaneously in older animals. They are considered to be reactive hyperplasia reflective of the burdens placed on the liver by the drug metabolism and excretion. Liver adenomas reported in humans generally seem to be absent in the dog (1).
Non-Tianor Pathologv
Pancreas Islets. In some dogs, there is an increase in pancreatic islet vacuolation (28), which may be related in some way to the decreased glucose tolerance described above. The vacuolation may rcsult from overstimulation of the islet cells in response to the decreasing glucose tolerance.
Uteritie Cystic Endornetrial Hyperplasia. Progestins are known to promote cystic endometrial hyperplasia in the dog but interestingly not tumors ofthe endometrium (9,28). The hyperplasia is florid and often involves adenomyosis (penetration of uterine glands into the uterine muscular wall, also known as endometriosis interna) even to the point of piercing through the serosa and into the abdominal cavity (R. F. McConnell, unpublished data).
The complication of pyometra is well-known and resulted in a number of hysterectomies, both therapeutic and prophylactic. In humans, the endometrium is not so sensitive to progestins and marked endometrial stimulation has not been a problem.
Gall Bladder. Many cases have been noted in the dog of cystic mucinous hyperplasia of the gall bladder (1 7, 28). There are no tumors associated with it and the exact cause is unknown. This condition has no apparent connection to the only human gall bladder condition associated with oral contraceptives, an increase in gall stones (17, 23) .
Adreiial Cortical Atrophy. It has been noted that high doses of some synthetic progestins lead to some degree of adrenal cortex atrophy in both rats and dogs (1, 17, 28, 34) . The mechanism of action is incompletely understood, but the present evidence suggests that these high doses of progesterone or . progestins display some inherent or induced glucocorticoid activity with subsequent-inhibition of pituitary release of adrenocorticotrophic hormone (1, 17) . The "Cushingoid" appearance of many animals may also be partly related to this finding. It has not been identified as'a human problem.
Eye Cataracts. Some dogs develop cataracts of the lens which appear to be related to increased blood glucose levels (28) . Cataracts are a known complication of spontaneous diabetes and it is likely that the elevated blood glucose levels are responsible for the cataracts in both cases. Oral contraceptives used by diabetic humans are considered to be a potential risk which requires careful monitoring (7) . Maimnary Gland Hyperplasia. Mammary gland hyperplasia of a generalized character is found and, where investigated, appears to be directly related to GH levels (28) .
Tumor Pathology (Table VII)
Three classes of tumors generally have been described in the dog following oral contraceptive dosing: mammary tumors, smooth muscle tumors of the tubular reproductive tract, and occasionally transitional cell. tumors of the urinary bladder.
Mainmary Tiiniors. Palpable mammary gland nodules in the dog are generally increased in size and number by oral contraceptives in a dose-related manner. The largest proportion of these nodules are nodular or focal hyperplasia but others are tumors of a benign or malignant nature with mixed mammary tumors (sometimes called carcinosarcomas if malignant) being common. The nodule and tumor types are not unusual since they can be found in the untreated dog population as well. The progestins of the 17-hydroxyprogesterone group are the most effective nodule stimulators with the 19-nortesterone group being more weakly stimulating or sometimes not detectably effective. The mechanism of action is now known to be related to the progestin stimulation ofGH release from the pituitary, particularly evident in the 17-hydroxyprogesterone group, with subsequent mammary nodule stimulation. This GH release is sometimes so stiong that it is accompanied by development of acromegaly from GH overstimulation. It has been sho? that control beagle dogs of 7 to 8 yr of age can each have dozens of microscopic nodules of hyperplastic and neoplastic tissue (5), so it is likely that the progestin-induced palpable nodules are not newly formed but are simply recruited from a pre-existing population. It has also been shown that some of the progestins originally thought to be non-tumor producing in the dog mammary gland actually can produce tumors if given in higher doses or by a different route such as by injection. It is increasingly clear that many progestins (including progesterone itself) can stimulate canine mammary nodule enlargement if given in an ade-. quate dose in the proper manner (1, 12) . However, a number of progestins, particularly of the 17-hydroxyprogesterone class, were withdrawn from development because of dog mammary tumors before TABLE VIL-Seven-year oral contraceptive studies in the dog: Pathology findings (tumor related).
Mammary gland-increased incidence of nodular hyperplasias and tumors 2. Uterus and vagina-increased incidence of leiomyoma and
Iciornyosarcoma (not seen in formulations containing only progestin) 3. Bladder-transitional epithelial cell tumors and hyperplasias in neck and triaone area (some studies)
it was firmly established that the mechanism of action had no relevance to the human and that most if not all progestins were likely to promote mammary nodule formation ifdose and route were properly varied (1, 12) . Sniooth Miiscle Tiiinors. The smooth muscle of the tubular reproductive tract (uterus, vagina) readily forms tumors in the dog called leiomyomata (leiomyomas and leiomyosarcomas) in response to increasing doses of estrogen. It should be recalled that not only is the E P ratio of the human formulations over balanced toward estrogen in the dog, but some of the progestins also have estrogenic influences as a species specific effect (27) . Because of the estrogen dependency of these tumors it has been said that "It is perhaps more accurate. . . to consider [reproductive tract] leiomyomas as endocrine-dependent lesions whose growth or size is dependent upon estrogens" (32) . The histological appearance can also vary with the nodules looking less benign with increasing estrogenic stimulation. This estrogenic effect is now well known in other species besides the dog (29) , including the human (6) . In guinea pigs, the effect is so marked that leiomyomas develop not only in the uterus, but also in the spleen, pancreas, and kidneys (24, 25). All of these lesions tend to regress when estrogen is removed. It is becoming increasingly evident that hormonal stimulation of tissues can result in tumors or tumor-like nodules. Trophic hormones are being associated with tumor formation in overstimulated target tissues not only in the case of estrogen but also for gastrin (stomach glandular tumors) (22) and thyroid stimulating hormone (thyroid tumors) (26). It would not be surprising if most, if not all, trophic hormones are one day associated with tumor formation in their respective target tissues when given to excess.
In the human, uterine leiomyomata are known by the misnomer "fibroids." These are commonly held to be benign growths because of their histologic appearance and usual behavior. However, the notion that all such growths are benign is misleading and has led to such interesting terminology as "benign metastasizing leiomyoma" for the rare case in which the histologically benign uterine tumor has equally innocent appearing metastases in the lung JOHNSON TOXICOLOGIC PATHOLOGY (6) . Leiomyomas can grow rapidly during pregnancy when the levels of estrogen increase and they may be suspected of being malignant at that time, although less than l% are actually malignant (6). Conversely, they tend to regress at menopause (6, 32) . Urinary Bladder Tiiinors. A Areas of hyperplasia are sometimes present instead of tumors. This finding has not been seen in rats or monkeys on oral contraceptive tests, nor reported in humans. Estrone implants in rats have caused similar tumors (lo), leading to speculation about a relationship to excessive estrogen. The mechanism of formation is not known, but the usual location in the neck or trigone area may be related to the embryological origin of the bladder. The bulk of the bladder is formed in a straight-forward manner from the allantoic membrane. However, the neck and portions near the trigone are derived from tissues that are under the influences of the reproductive tract until near the end of embryologic development (30). These areas presumably retain the ability to respond to endocrine influences more readily than the bulk of the bladder, which may be the reason for the preferred location of the hyperplasias and tumors.
CONCLUSIONS
As might be expected with almost any animal model system, the 7-yr dog oral contraceptive studies have resulted in some information that has been predictive for humans, some that has not been predictive, and some information that was irrelevant because of known species differences.
A number of findings were predictive of potential risks in humans, including the development of leiomyomata from estrogen excess, glucose tolerance problems, increased liver enzymes, and reduced red blood cell indices. Some findings have so far turned out to be non-predictive for human problems including tumors of the urinary bladder and gall bladder hyperplasia. By the same token, some findings in humans were not predictable by the dog studies, such as liver adenomas and blood clotting tendencies. Lastly, one finding that appears to be irrelevant to human prediction because of known species differences is the mammary tumors.
In this case, the limitations of the dog model have been demonstrated by elucidation of the specific mechanisms of action. The growth hormone-dependent mammary, tumors that are seen in the dog are known to have no counterpart in the human.
Decisions to withdraw a contraceptive drug of this nature from development due solely to the presence of mammary nodules or tumors in the dog is no longer a scientifically defensible position. , 1.
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